Psychopharmacological Drugs Advisory Committee

February 15, 2001

Briefing Information

NDA 20-919: Zeldox (ziprasidone mesylate IM, Pfizer.)

Pfizer Global Research & Development

Disclaimer

The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Briefing Information

Appendix

Pfizer July 19, 2000 submission

Food and Drug Administration

Overview

Review and Evaluation of Clinical Data

Statistical Review and Evaluation